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A B S T R A C T
Purpose
To determine whether adjuvant tamoxifen treatment for breast cancer (BC) is associated with
reduced contralateral breast cancer (CBC) risk for BRCA1 and/or BRCA2 mutation carriers.
Methods
Analysis of pooled observational cohort data, self-reported at enrollment and at follow-up from the
International BRCA1, and BRCA2 Carrier Cohort Study, Kathleen Cuningham Foundation Consor-
tium for Research into Familial Breast Cancer, and Breast Cancer Family Registry. Eligible women
were BRCA1 and BRCA2 mutation carriers diagnosed with unilateral BC since 1970 and no other
invasive cancer or tamoxifen use before first BC. Hazard ratios (HRs) for CBC associated with
tamoxifen use were estimated using Cox regression, adjusting for year and age of diagnosis,
country, and bilateral oophorectomy and censoring at contralateral mastectomy, death, or loss
to follow-up.
Results
Of 1,583 BRCA1 and 881 BRCA2 mutation carriers, 383 (24%) and 454 (52%), respectively, took
tamoxifen after first BC diagnosis. There were 520 CBCs over 20,104 person-years of observation.
The adjusted HR estimates were 0.38 (95% CI, 0.27 to 0.55) and 0.33 (95% CI, 0.22 to 0.50) for
BRCA1 and BRCA2 mutation carriers, respectively. After left truncating at recruitment to the
cohort, adjusted HR estimates were 0.58 (95% CI, 0.29 to 1.13) and 0.48 (95% CI, 0.22 to 1.05)
based on 657 BRCA1 and 426 BRCA2 mutation carriers with 100 CBCs over 4,392 person-years
of prospective follow-up. HRs did not differ by estrogen receptor status of the first BC (missing for
56% of cases).
Conclusion
This study provides evidence that tamoxifen use is associated with a reduction in CBC risk for
BRCA1 and BRCA2 mutation carriers. Further follow-up of these cohorts will provide increased
statistical power for future prospective analyses.
J Clin Oncol 31:3091-3099. © 2013 by American Society of Clinical Oncology
INTRODUCTION
Womenwho carry amutation inBRCA1 orBRCA2
have a high lifetime risk of breast cancer (BC).1
Bilateral mastectomy and premenopausal bilat-
eral salpingo-oophorectomy (BSO) are associated
with a reduced BC risk of greater than 90%2,3 and
approximately 50%, respectively,4 but are not ac-
ceptable interventions for many women.5,6 Ran-
domized, placebo-controlled primary prevention
trials of women who are at increased risk of BC
have shown that selective estrogen receptor mod-
ulators (SERMs), such as tamoxifen, reduce BC
risk by 40%.7-11The preventive effect of tamoxifen
is sustained for at least 5 years after cessation of
therapy,11 and the absolute risk of serious adverse
effects is low, particularly for premenopausal
women.9,12 For women in the general population,
randomized controlled trials have also shown that
adjuvant tamoxifen treatment after a first BC di-
agnosis halves the risk of contralateral breast can-
cer (CBC).13 However, it is uncertain whether
tamoxifen has any efficacy for women carrying
mutations in BRCA1 or BRCA2, and it is not
commonly prescribed to carriers14,15 for the pur-
pose of BC prevention.
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Inadequate data regarding efficacy is amajor barrier to prescrib-
ing SERMS to BRCA1 and BRCA2mutation carriers to prevent BC.16
Randomized primary prevention trials of mutation carriers are un-
likely to be feasible and would take many years to generate reliable
conclusions. Prospective observational studies of the efficacy of
SERMS for primary prevention of BC would depend on uptake of
tamoxifen by mutation carriers and would also take many years. Yet
the issue is an important one right now for the tens of thousands of
women who currently know that they carry a BRCA1 or BRCA2
mutation. Information about the efficacy or otherwise of tamoxifen
for the prevention of CBC could assist BRCA1 and BRCA2mutation
carriers make decisions about whether to take tamoxifen for primary
BC prevention. It might also have implications for the adjuvant treat-
ment of BRCA1 and BRCA2 mutation carriers who do not wish to
have bilateral mastectomy after an initial diagnosis of a hormone
receptor–negative BC.
The aimof this studywas to determinewhether adjuvant tamox-
ifen treatment for first BC is associated with a reduction in the risk of
CBC for BRCA1 and/or BRCA2 mutation carriers and whether the
strength of any association differs according to the estrogen receptor
(ER) status of the first BC.
METHODS
Participants
Participants were female BRCA1 or BRCA2mutation carriers from Eu-
rope, Australia, New Zealand, the United States, and Canada, enrolled be-
tween September 1, 1993, and December 2, 2009, in three cohort studies; the
International BRCA1 and BRCA2Carrier Cohort Study (IBCCS),17 the Kath-
leen Cuningham Foundation Consortium for Research into Familial Breast
Cancer (kConFab),18 and the Breast Cancer Family Registry (BCFR).19 All
cohorts include participants recruited through BC family clinics, and the
BCFR also includes some population-based recruitment. All participants pro-
videdwritten informed consent, and all studies were approved by the relevant
institutional review boards.
A woman was eligible for the current study if she had a pathogenic
mutation in BRCA1 or BRCA2 and a BC diagnosed since 1970 (when tamox-
ifen started to be prescribed for early-stage BC) that was not bilateral at the
time of diagnosis (defined as within 6 months of first BC diagnosis). Women
with a history of other invasive cancers or tamoxifen use before their first BC
were excluded.
Data Collection
Information on family cancer history, demographics, potential risk fac-
tors for BC (eg, exogenous hormone use, alcohol intake, and reproductive
history), uptake of surgical and medical prevention strategies, and cancer
treatment including use of tamoxifen and chemotherapy was self-reported at
cohort entry and at follow-up. Cancer outcomes were self-reported and/or
collected by linkage with a cancer registry. Each study in each cohort collected
this information systematically using similar questionnaires. Frequency of
follow-upvariedbetween studies. Pathologydatawere abstracted fromseveral
sources, including diagnostic pathology reports, medical records, and cancer
registry records, or through central pathology review.
Statistical Analysis
Participants were considered to have used tamoxifen if they took it for
any period of time after their first BC diagnosis. Hazard ratios (HRs) for CBC
associatedwith tamoxifen use (no, yes) after first BC, excluding use afterCBC,
were estimated separately forBRCA1 andBRCA2mutation carriers usingCox
regression,modeling time fromfirst BCdiagnosis to thedevelopment ofCBC.
Analysis time was censored at the date of contralateral mastectomy, death, or
last follow-up.
Two main analyses were performed. The first combined retrospective
(ie, time before cohort entry) and prospective (ie, time after cohort entry)
follow-up. For this analysis, all women were eligible, and follow-up started at
date of diagnosis of the first BC. To investigate whether the inclusion of
prevalent CBC cases may have introduced bias, a second analysis was per-
formed that applied left truncation of analysis time at the date of cohort entry
and therefore considered outcome data from prospective follow-up only.
Age and year of diagnosis (both continuous), country of residence (categori-
cal), and BSO (dichotomous, time-varying) were considered as covariates in
all multivariable analyses and were included in analyses of retrospective
follow-updata.Adjustment for yearofdiagnosis andBSOmadenosubstantial
difference toHRestimates fromtheanalysesofprospectivedataonly; given the
smaller number of contralateral events, only age at diagnosis and country of
residence were included in the final prospective models. Robust estimates of
variancewerederived toaccount for thenonindependenceofwomenfromthe
same family. ER status of the first BC was considered as a covariate and as a
stratifying variable in separate multivariable analyses of the combined retro-
spective and prospective data. Sensitivity analyses were undertaken using the
combined and prospective-only data.
These included stratifying by menopausal status at diagnosis of the first
BC, adjusting for chemotherapy use (no, yes) and histologic subtype (lobular,
nonlobular), adjusting for use of oral contraceptives (no, yes) or hormone
replacement therapy after thefirstBCdiagnosis (no, yes), excluding thosewho
took other endocrine therapy (eg, aromatase inhibitors or gonadotropin-
releasing hormone agonists) after the first BC, and censoring at the date of the
first subsequent ipsilateral breast event or at diagnosis of the first nonbreast
primary cancer.
All statistical analyseswere conductedusing STATA10 (STATA,College
Station,TX).Gene-specificpost hocpower calculationswere carriedoutusing
StatCalc in Epi Info20 based on the number of participants the observed
prevalence of tamoxifen use, and the observed 11% of nonusers who devel-
oped contralateral disease during follow-up.
RESULTS
A total of 3,267BRCA1 andBRCA2mutation carriers with a personal
history of BC were identified from the three cohorts. Of these, 803
were excluded because of first BC diagnosis before 1970 (n  107),
CBCoccurringwithin6months after thefirstBCdiagnosis (n115),
no follow-up after the first BC diagnosis (n  130), other invasive
cancerbeforefirstBCdiagnosis (n86),useof tamoxifenbefore their
firstBCdiagnosis (n34), andmissing informationontamoxifenuse
or information only available from a relative (proxy; n 331). Thus
the final sample of 2,464 women comprised 1,583 BRCA1 and 881
BRCA2mutation carriers, 95.7% of whom were ascertained through
BC family clinics and an estimated 96% of whom were of white
European origin. Prospective follow-up data (since date of cohort
entry)were available for 1,083women (44%), comprising 657BRCA1
and 426BRCA2mutation carriers who had been diagnosedwith their
first BC amedian of 3.9 years before study entry.
Participant characteristics are showninTable1.Themedian time
since diagnosis of first BC was 6.6 years, and the median time since
cohort entrywas3.2years.ERstatusof thefirstBCwasknownfor44%
of women.Where ER status was known, the first BC was ER negative
for 76% of BRCA1 mutation carriers and ER positive for 77% of
BRCA2mutation carriers. In total, 24%ofBRCA1 and52%ofBRCA2
mutation carriers used tamoxifen after their first BC. Overall, 67% of
those with an ER-positive first BC used tamoxifen (60% and 71% for
BRCA1 and BRCA2 mutation carriers, respectively) compared with
17% of those with an ER-negative first BC (15% and 25%, respec-
tively).A total of 581BRCA1mutation carriers (37%)and289BRCA2
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mutation carriers (33%) underwent BSO, either before (n 64 and
44, respectively) or after (n 517 and 245, respectively) their first BC.
Several tumor and patient characteristics are associated with risk
of CBC,21,22 although there are only limited data on these associations
for BRCA1 and BRCA2 mutation carriers.23-25 Table 2 compares ta-
moxifen users and nonusers with regard to such characteristics. Ta-
moxifen users tended to be older at first BC diagnosis (P  .001),
which was more likely to have been ER positive (P .001) and of
lobular histology (P .01). Tamoxifen users were also more likely
to have received chemotherapy (P  .001) and to have had BSO
(P .001).
Table 1. Participant Characteristics
Characteristic
BRCA1
Mutation
Carriers
(n  1,583)
BRCA2
Mutation
Carriers
(n  881)
No. % No. %
Data available
Retrospective only 926 58 455 52
Prospective 657 42 426 48
Follow-up in years
Since first BC diagnosis
Median 6.5 6.6
Interquartile range 3.0-11.8 3.0-11.2
Since cohort enrollment
Median 3.4 3.1
Interquartile range 2.0-6.1 1.6-6.0
Cohort
IBCCS 1,063 67 509 58
kConFab 321 20 242 27
BCFR 199 13 130 15
Country of residence
Australia 286 18 226 26
Austria 65 4 18 2
Canada 47 3 44 5
France 267 17 143 16
Italy 21 1 10 1
New Zealand 21 1 8 1
Poland 50 3 0
Spain 41 3 48 5
The Netherlands 202 13 31 4
United States of America 181 11 117 13
United Kingdom 297 19 204 23
Other 105 7 32 4
Year of first BC diagnosis
1970-1979 97 6 35 4
1980-1989 341 22 157 18
1990-1999 815 51 442 50
 2000 330 21 247 28
Age at first BC diagnosis, years
40 801 51 311 35
40-49 527 33 355 40
50-59 200 13 159 18
 60 55 3 56 6
Menopausal status at first BC
diagnosis
Pre/perimenopausal 1,349 85 691 78
Postmenopausal 234 15 190 22
Estrogen receptor status of first BC
Negative 504 32 100 11
Positive 157 10 331 38
Unknown 922 58 450 51
Took tamoxifen for first BC
No 1,200 76 427 48
Yes 383 24 454 52
Yes, ER-negative first BC 76 15 25 25
Yes, ER-positive first BC 94 60 234 71
Chemotherapy administered for
first BC
No 233 15 148 17
Yes 717 45 366 42
Unknown 633 40 367 42
(continued in next column)
Table 1. Participant Characteristics (continued)
Characteristic
BRCA1
Mutation
Carriers
(n  1,583)
BRCA2
Mutation
Carriers
(n  881)
No. % No. %
Bilateral oophorectomy
No 1,002 63 592 67
Yes 581 37 289 33
Abbreviations: BC, breast cancer; BCFR, Breast Cancer Family Registry; ER,
estrogen receptor; IBCCS, International BRCA1, and BRCA2 Carrier Cohort
Study; kConFab, Kathleen Cuningham Foundation Consortium for Research
into Familial Breast Cancer.
European countries, with the exception of eight BRCA1 mutation carriers
and one BRCA2 mutation carrier from other countries.
Table 2. Characteristics Potentially Associated With Contralateral BC Risk:
Tamoxifen Users Versus Nonusers
Characteristic
Tamoxifen
Users
Tamoxifen
Nonusers
P No. % No. %
Mutation type  .001
BRCA1 383 46 1,200 74
BRCA2 454 54 427 26
Age at first BC, years  .001
Median 43 40
Interquartile range 37-49 34-47
Estrogen receptor status of
first BC
Negative 101 24 502 76
Positive 328 76 160 24  .001
Unknown 408 965
Histology of first BC
Lobular 19 3 16 2
Nonlobular 532 97 1,039 98 .01
Unknown 286 572
Chemotherapy administered for
first BC
No 105 21 276 29
Yes 399 79 684 71 .001
Unknown 333 667
Bilateral oophorectomy
No 486 58 1,108 68
Yes 351 42 519 32  .001
Abbreviation: BC, breast cancer.
Determined using Fisher’s exact test on known values for all characteristics
except age, for which the rank-sum test was applied.
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CBCs occurred in 520 women (24% of BRCA1 and 17% of
BRCA2 mutation carriers), and 100 of these occurred after cohort
entry. Results from Cox regression analysis assessing an association
between tamoxifen use after first BC and risk of CBC are shown in
Table 3 and Figure 1. For BRCA1mutation carriers, from analysis of
the combined retrospective and prospective data, the estimated HR
was0.38 (95%CI, 0.27 to0.55;P .001). Fromanalysis usingonly the
prospective data, the estimated HR was 0.58 (95% CI, 0.29 to 1.13;
P .1). For BRCA2mutation carriers, the corresponding HRs were
0.33 (95% CI, 0.22 to 0.50; P .001) and 0.48 (95% CI, 0.22 to 1.05;
P .07), respectively. There were no significant differences in the
HR estimates between BRCA1 and BRCA2mutation carriers using
the combined data (Pheterogeneity .7) or the prospective data only
(Pheterogeneity  .9), nor were the results different between BRCA1
and BRCA2mutation carriers based on the retrospective data only
(Pheterogeneity  .7). Analyses of combined data adjusting for, or
stratifying on, ER status of the first BC revealed that the observed
associations were not accounted for by this tumor characteristic;
there was no evidence that the HRs for tamoxifen use differed by
ER status (Pheterogeneity .3 and .3 forBRCA1 andBRCA2mutation
carriers, respectively), although the number of ER-positive BCs in
BRCA1 mutation carriers and ER-negative BCs in BRCA2 muta-
tion carriers was small (Table 4). The results from all sensitivity
analyses were similar (Table 5).
For BRCA1 mutation carriers who were premenopausal at first
BC diagnosis, the association of reduced BC risk with tamoxifen was
weaker for those who underwent BSO compared with those who did
not (using combined retrospective and prospective data, HR 0.70
[95% CI, 0.32 to 1.53] v 0.26 [95% CI, 0.16 to 0.43]; Pheterogeneity 
.004). This differencewas less evident when the analysis was restricted
to the prospective data (HR 0.61 [95%CI, 0.23 to 1.65] v 0.40 [95%
CI,0.12 to1.32];Pheterogeneity .3).ForBRCA2mutationcarriers from
the combined data, the corresponding HR estimates were 0.70 (95%
CI, 0.27 to 1.82) versus 0.21 (95%CI, 0.12 to 0.36;Pheterogeneity .08),
and fromprospective data only, they were 0.76 (95%CI, 0.10 to 5.64)
versus 0.33 (95%CI, 0.06 to 1.91; Pheterogeneity .5).
DISCUSSION
In this study, use of tamoxifen after first BC was associated with
reduced risk of CBC for BRCA1 and BRCA2mutation carriers based
Table 3. Association Between Tamoxifen Use After First BC and CBC
Variable No. Person-Years
CBC
HR 95% CI PNo. %/Person-Year
BRCA1 mutation carriers
Combined data
Took tamoxifen for first BC
No 1,200 9,893 338 3.4 1.00
Yes 383 3,086 35 1.1 0.38 0.27 to 0.55  .001
Prospective data only
Took tamoxifen for first BC
No 481 1,989 54 2.7 1.00
Yes 176 716 12 1.7 0.58† 0.29 to 1.13 .1
BRCA2 mutation carriers
Combined data
Took tamoxifen for first BC
No 427 3,762 115 3.1 1.00
Yes 454 3,364 32 1.0 0.33 0.22 to 0.50  .001
Prospective data only
Took tamoxifen for first BC
No 191 791 21 2.7 1.00
Yes 235 896 13 1.5 0.48† 0.22 to 1.05 .07
Abbreviations: BC, breast cancer; CBC, contralateral breast cancer; HR, hazard ratio.
Adjusted for age at diagnosis (continuous), year of diagnosis (continuous), bilateral prophylactic oophorectomy (time varying), and country of residence (categorical,
as per Table 1).
†Adjusted for age at diagnosis (continuous) and country (categorical: Australia, Canada, France, United States, United Kingdom, other).
BR
CA
1
BR
CA
2
Hazard Ratio
All data
All data (ER+)
All data (ER-)
Prospective
data only
All data (ER+)
All data (ER-)
All data
Prospective
data only
0 0.2 0.4 0.80.6 1.0 1.2 1.4 1.6
HR (95% CI)
0.38 (0.27 to 0.55)
0.33 (0.13 to 0.79)
0.59 (0.23 to 1.52)
0.58 (0.29 to 1.13)
0.33 (0.22 to 0.50)
0.44 (0.14 to 1.35)
0.30 (0.15 to 0.62)
0.48 (0.22 to 1.05)
Fig 1. Hazard ratio (HR) estimates (represented by circles) and corresponding
95% CIs (represented by horizontal lines) for risk of contralateral breast cancer
associated with tamoxifen use by women with BRCA1 mutations (BRCA1) and
BRCA2mutations (BRCA2). Separate estimates are provided based on combined
retrospective and prospective data, overall, and by estrogen receptor (ER) status
and on prospective data only.
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oncombined retrospective andprospectivedata.Nodifferences in the
reduction of risk associated with tamoxifen use were found by the ER
status of the first BC. Our findings are consistent with those of other
smaller observational studies that used retrospective data26-29 and
strengthen those findings.
Only one other prospective study has examined the association
between tamoxifen use and BC risk for BRCA1 and BRCA2mutation
carriers. In the primary prevention setting, a substudy of a double-
blind, placebo-controlled trial estimated theHRs for BCwith tamox-
ifen use to be 1.67 (95% CI, 0.32 to 10.7) and 0.38 (95% CI, 0.06 to
1.56) for BRCA1 and BRCA2 mutation carriers, respectively15; the
wideCIs suggest that these analyseswere essentially uninformative. In
the current study, when the analyses were restricted to prospective
data only, there was only weak evidence that tamoxifen use is associ-
ated with reduced risk of CBC, with statistically nonsignificant HR
estimates that were less than 1. The post hoc power for the analysis of
prospective data only was limited; for each of BRCA1 and BRCA2
mutation carriers, there was 80% power at P .05 to detect HRs of
0.35 or less. Therefore, our statistically nonsignificant findings from
analysis of the prospective data only should not necessarily be inter-
preted as a lack of confirmation of the highly significant results from
theanalysisof thepooledretrospectiveandprospectivedata, especially
given the consistency in the HR estimates from the two analyses.
Previous studies have suggested that tamoxifen use only reduces
the risk of ER-positive BC.7-11 The majority (75% to 80%) of BCs
arising in BRCA2 mutation carriers are ER positive,30 whereas most
BCs arising inBRCA1mutation carriers are ERnegative at the time of
diagnosis.31 Nevertheless, estrogen might be important in the patho-
genesis of BCs in BRCA1 mutation carriers, particularly given the
observation that premenopausal bilateral oophorectomy is associated
with reduced BC risk for BRCA1mutation carriers3 and that preclin-
ical data suggest that BRCA1-associated BCs may have an estrogen-
responsive occult phase.32-34 A link between estrogen and BC
development in BRCA1mutation carriers is suggested by the finding
that two single-nucleotide polymorphisms located close to ESR1
(which encodes ER) are associatedwithBC risk inBRCA1mutation
carriers.35 Furthermore, ER  is commonly expressed in BCs of
BRCA1 mutation carriers36,37 and could be a target for tamoxifen.38
Thus there are important plausible mechanisms by which tamoxifen
might prevent BC for both BRCA1 and BRCA2mutation carriers.39
BRCA1 and BRCA2 mutation carriers have increased risks of
both breast and high-grade serous gynecologic cancers.1 Given that
screening for the latter is ineffective,40-45 many carriers elect to un-
dergo premenopausal BSO, which dramatically reduces their risk of
serous gynecologic cancer and is associatedwith about ahalvingofBC
risk.4 Therefore, in the primary prevention setting, an important clin-
ical question is whether tamoxifen use might further reduce BC risk
for mutation carriers who have had premenopausal BSO. Although
we could not distinguish between pre- and postmenopausal BSO, our
findings suggest that the inverse association between tamoxifen use
and risk of CBC is stronger if ovaries are still in situ.
The strengths of the current study include the systematic data
collection and the inclusion of women with an ER-negative first BC
who received tamoxifen. The latter occurred because in many coun-
tries in the 1970s and early 1980s, adjuvant tamoxifen was prescribed
to postmenopausal womenwith BC irrespective of hormone receptor
status. Another strength of this study is the relatively large sample size,
although, despite this, prospective data were limited.
A major limitation of the study is the nonrandomized design,
which could have resulted in biased estimates owing to nonrandom
use of tamoxifen. Compared with nonusers, tamoxifen users were
significantly older andmore likely tohavehad anER-positive first BC,
to have received chemotherapy, and to have had BSO, all features
generally associated with reduced risk of CBC. However, adjustment
for age at diagnosis and ER status of the first BC in multivariate
analysis, as well as stratifying on ER status, made no substantive dif-
ference to the results. Sensitivity analyses showed little influence of
adjustment for chemotherapyorhistologic subtype.Thus it is unlikely
that our finding of an association between tamoxifen use and reduced
CBC is explained solely by nonrandom use of tamoxifen.
A randomized study to address this secondary prevention ques-
tion is unlikely to be feasible given that (1) a substantial proportion of
youngmutation carriers undergo contralateralmastectomyafter their
first BC diagnosis,46,47 and (2) it could only be conducted in women
with ER-negative BC because adjuvant endocrine therapy (with ta-
moxifen and/or an aromatase inhibitor) is the standard of care for
Table 4. Analysis by ER Status of First Breast Cancer (combined retrospective and prospective data)
Variable No Tam Tam
Person-Years
CBC
HR 95% CI P
No Tam Tam
No Tam Tam No. %/Person-Year No. %/Person-Year
BRCA1 mutation carriers
ER negative 428 76 2,628 521 95 3.6 6 1.2 0.33† 0.13 to 0.79 .01
ER positive 63 94 482 547 12 2.5 7 1.3 0.59 0.23 to 1.52 .3
Adjusted for ER status 491 170 3,110 1,068 107 3.4 13 1.2 0.44‡ 0.25 to 0.85 .01
BRCA2 mutation carriers
ER negative 75 25 531 264 14 2.6 3 1.1 0.44 0.14 to 1.35 .2
ER positive 97 234 558 1,428 22 3.9 14 1.0 0.30† 0.15 to 0.62 .001
Adjusted for ER status 172 259 1,090 1,692 36 3.3 17 1.0 0.33‡ 0.17 to 0.64 .001
Abbreviations: CBC, contralateral breast cancer; ER, estrogen receptor; HR, hazard ratio; No Tam, did not take tamoxifen for first breast cancer; Tam, took tamoxifen
for first breast cancer.
Adjusted for age at diagnosis (continuous).
†Adjusted for age at diagnosis (continuous) and country of residence (categorical: Australia, France, the Netherlands, United Kingdom, United States, other).
‡Adjusted for age at diagnosis (continuous), year of diagnosis (continuous), bilateral prophylactic oophorectomy (time varying), and country of residence
(categorical, as in †).
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Table 5. Association Between Tamoxifen Use and Risk of CBC: Sensitivity Analyses
Variable No. CBC Person-Years HR 95% CI
BRCA1 mutation carriers
Combined data
Main analysis 1,583 373 12,979 0.38 0.27 to 0.55
Premenopausal women 1,312 329 11,045 0.35 0.24 to 0.53
Postmenopausal women 234 35 1,699 0.51 0.20 to 1.29
Chemotherapy use known 950 194 7,306 0.41 0.26 to 0.67
Adjusted for chemotherapy 950 194 7,306 0.41 0.25 to 0.67
Histology of first BC known 1,047 244 8,076 0.33 0.20 to 0.53
Adjusted for histology 1,047 244 8,076 0.33 0.20 to 0.54
Adjusted for use of OC or HRT 1,583 373 12,979 0.38 0.27 to 0.55
Excluding women who used OC or HRT 1,419 345 11,536 0.35 0.24 to 0.51
Excluding women who used other endocrine therapy 1,574 372 12,940 0.38 0.27 to 0.55
Censoring at ipsilateral events after first BC 1,572 351 12,499 0.38 0.26 to 0.56
Censoring at diagnosis of non-breast primary cancers 1,580 364 12,495 0.35 0.24 to 0.51
Prospective data only†
Main analysis 657 66 2,705 0.58 0.29 to 1.13
Premenopausal women 550 59 2,295 0.55 0.27 to 1.13
Postmenopausal women 93 5 357 —
Chemotherapy use known 385 39 1,827 0.61 0.26 to 1.48
Adjusted for chemotherapy 385 39 1,827 0.60 0.25 to 1.47
Histology of first BC known 297 37 1,207 0.43 0.17 to 1.08
Adjusted for histology 297 37 1,207 0.45 0.18 to 1.14
Adjusted for use of OC or HRT 657 66 2,705 0.57 0.29 to 1.12
Excluding women who used OC or HRT 579 60 2,379 0.56 0.28 to 1.11
Excluding women who used other endocrine therapy 649 65 2,688 0.58 0.29 to 1.15
Censoring at ipsilateral events after first BC 629 60 2,588 0.58 0.28 to 1.18
Censoring at diagnosis of non-breast primary cancers 609 62 2,462 0.49 0.23 to 1.01
BRCA2 mutation carriers
Combined data
Main analysis 881 147 7,125 0.33 0.22 to 0.50
Premenopausal women 667 117 5,559 0.28 0.17 to 0.46
Postmenopausal women 190 26 1,382 0.41 0.18 to 0.92
Chemotherapy use known 514 78 4,117 0.39 0.22 to 0.70
Adjusted for chemotherapy 514 78 4,117 0.41 0.23 to 0.75
Histology of first BC known 559 95 4,212 0.43 0.26 to 0.72
Adjusted for histology 559 95 4,212 0.43 0.26 to 0.72
Adjusted for use of OC or HRT 881 147 7,124 0.32 0.22 to 0.49
Excluding women who used OC or HRT 803 136 6377 0.35 0.23 to 0.53
Excluding women who used other endocrine therapy 863 146 7,051 0.33 0.22 to 0.49
Censoring at ipsilateral events after first BC 869 138 6,823 0.37 0.24 to 0.56
Censoring at diagnosis of non-breast primary cancers 880 143 6,943 0.32 0.21 to 0.48
Prospective data only†
Main analysis 426 34 1,687 0.48 0.22 to 1.05
Premenopausal women 321 23 1,301 0.58 0.21 to 1.61
Postmenopausal women 91 8 348 0.35 0.08 to 1.48
Chemotherapy use known 256 26 1,182 0.43 0.16 to 1.15
Adjusted for chemotherapy 256 26 1,182 0.55 0.21 to 1.45
Histology of first BC known 195 23 692 0.79 0.31 to 2.05
Adjusted for histology 195 23 692 0.78 0.31 to 1.99
Adjusted for use of OC or HRT 426 34 1,687 0.45 0.21 to 0.99
Excluding women who used OC or HRT 386 32 1,512 0.46 0.21 to 1.04
Excluding women who used other endocrine therapy 412 33 1,650 0.47 0.21 to 1.05
Censoring at ipsilateral events after first BC 410 31 1,607 0.48 0.21 to 1.08
Censoring at diagnosis of non-breast primary cancers 412 32 1,586 0.46 0.20 to 1.05
Abbreviations: BC, breast cancer; CBC, contralateral breast cancer; HR, hazard ratio; HRT, hormone replacement therapy; OC, oral contraceptive.
Analysis adjusted for age at diagnosis (continuous), year of diagnosis (continuous), bilateral prophylactic oophorectomy (time varying), and country of
residence (categorical).
†Analysis adjusted for age at diagnosis (continuous) and country (categorical).
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ER-positive first BC.Certainly itwould takemany years to initiate and
complete such a trial so that results would not be available for more
than a decade.
The large proportion of participants in the current study with
missing ERdata for the first BC reduced the power of the correspond-
ing stratified analysis. Nevertheless, because ER status is associated
with both tamoxifen use and risk of CBC,22 it is convincing that the
stratified analyses gave consistent results.
The analyses of all data combined included prevalent cases of BC
and therefore could be subject to survival bias. For this reason, we
repeated the analyses using prospective data only. The results were
consistent, but the inverse associations were somewhat attenuated.
Tamoxifen has not been widely prescribed for primary preven-
tion of BC for BRCA1 and BRCA2mutation carriers, in part because
there has been inadequate evidence of efficacy.16 The data presented
here add to the current evidence base. Some cliniciansmight consider
the statistically significant inverse association between tamoxifen use
and development of CBC, seen in the combined analysis, as adequate
reason to prescribe tamoxifen for BC prevention in BRCA1 and
BRCA2mutation carriers, despite the fact that the associationwas not
confirmed by the less strongly powered prospective analysis. Others
might not consider the evidence to be sufficient. Becausemutations in
BRCA1 and BRCA2 are associated with early-onset BC, premeno-
pausal women are the most relevant group in this setting. Tamoxifen
can cause hot flushes and night sweats, but for premenopausal
women, themainseriousadverse effect isdeepvenous thrombosis; the
risk is similar to that from use of the combined oral contraceptive
pill.48,49 Endometrial cancer risk is increased for women who take
tamoxifen for treatment of BC or for BC prevention. Some small
retrospective observational studies have suggested increased endome-
trial cancer risk specifically for BRCA1 and BRCA2mutation carriers
who take tamoxifen,50,51 although cautionmust be exercised in inter-
preting these findings.52 Therefore, for BRCA1 and BRCA2mutation
carriers with breast tissue, particularly those who have not undergone
premenopausal BSO, the option of tamoxifen for BC prevention
should perhaps be discussed along with the evidence of benefits and
potential adverse effects, allowing women themselves to decide
whether they wish to use the medication.
This study provides observational evidence that, for BRCA1 and
BRCA2mutation carriers, tamoxifenuse for first BCmight reduce the
risk of CBC. Further follow-up of these cohorts will provide increased
statistical power for prospective analyses and thus a more definitive
answer to this important question in the future.
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS
OF INTEREST
The author(s) indicated no potential conflicts of interest.
AUTHOR CONTRIBUTIONS
Conception and design: Kelly-Anne Phillips, Roger L. Milne, Douglas F.
Easton, Michael L. Friedlander, Nadine Andrieu, John L. Hopper
Financial support: Kelly-Anne Phillips, Melissa C. Southey, John
L. Hopper
Administrative support: Prue C. Weideman, Kate Birch
Provision of study materials or patients: Kelly-Anne Phillips, Matti A.
Rookus, Mary B. Daly, Antonis C. Antoniou, Michael L. Friedlander,
Saundra S. Buys, Sue Anne McLachlan, Esther M. John, Maartje J.
Hooning, Rob A.E.M. Tollenaar, Trinidad Caldes, Irene L. Andrulis,
Melissa C. Southey, Håkan L. Olsson, Edith Olah, John L. Hopper
Collection and assembly of data: Kelly-Anne Phillips, Matti A. Rookus,
Mary B. Daly, Antonis C. Antoniou, Susan Peock, Debra Frost, Douglas
F. Easton, Steve Ellis, Michael L. Friedlander, Saundra S. Buys, Catherine
Nogue`s, Dominique Stoppa-Lyonnet, Vale´rie Bonadona, Sue Anne
McLachlan, Esther M. John, Maartje J. Hooning, Caroline Seynaeve, Rob
A.E.M. Tollenaar, David E. Goldgar, Mary Beth Terry, Trinidad Caldes,
Prue C. Weideman, Irene L. Andrulis, Christian F. Singer, Kate Birch,
Jacques Simard, Melissa C. Southey, Håkan L. Olsson, Anna Jakubowska,
Edith Olah, Anne-Marie Gerdes, Lenka Foretova, John L. Hopper
Data analysis and interpretation: Kelly-Anne Phillips, Roger L. Milne,
Matti A. Rookus, Antonis C. Antoniou, Douglas F. Easton, Michael L.
Friedlander, Pascal Pujol, Sue Anne McLachlan, Maartje J. Hooning,
John L. Hopper
Manuscript writing: All authors
Final approval of manuscript: All authors
REFERENCES
1. Antoniou A, Pharoah PD, Narod S, et al:
Average risks of breast and ovarian cancer associ-
ated with BRCA1 or BRCA2 mutations detected in
case Series unselected for family history: A com-
bined analysis of 22 studies. Am J Hum Genet
72:1117-1130, 2003
2. Lostumbo L, Carbine NE, Wallace J: Prophy-
lactic mastectomy for the prevention of breast
cancer. Cochrane Database Syst Rev CD002748,
2010
3. Domchek SM, Friebel TM, Singer CF, et al:
Association of risk-reducing surgery in BRCA1 or
BRCA2 mutation carriers with cancer risk and mor-
tality. JAMA 304:967-975, 2010
4. Rebbeck TR, Kauff ND, Domchek SM: Meta-
analysis of risk reduction estimates associated with
risk-reducing salpingo-oophorectomy in BRCA1 or
BRCA2 mutation carriers. J Natl Cancer Inst 101:80-
87, 2009
5. Phillips KA, Jenkins MA, Lindeman GJ, et al:
Risk-reducing surgery, screening and chemopreven-
tion practices of BRCA1 and BRCA2 mutation carri-
ers: A prospective cohort study. Clin Genet 70:
198-206, 2006
6. Metcalfe KA, Birenbaum-Carmeli D, Lubinski
J, et al: International variation in rates of uptake of
preventive options in BRCA1 and BRCA2 mutation
carriers. Int J Cancer 122:2017-2022, 2008
7. Powles TJ, Ashley S, Tidy A, et al: Twenty-
year follow-up of the Royal Marsden randomized,
double-blinded tamoxifen breast cancer prevention
trial. J Natl Cancer Inst 99:283-290, 2007
8. Fisher B, Costantino JP, Wickerham DL, et al:
Tamoxifen for the prevention of breast cancer: Cur-
rent status of the National Surgical Adjuvant Breast
and Bowel Project P-1 study. J Natl Cancer Inst
97:1652-1662, 2005
9. Veronesi U, Maisonneuve P, Rotmensz N, et
al: Tamoxifen for the prevention of breast cancer:
Late results of the Italian Randomized Tamoxifen
Prevention Trial among women with hysterectomy.
J Natl Cancer Inst 99:727-737, 2007
10. Cuzick J, Powles T, Veronesi U, et al: Over-
view of the main outcomes in breast-cancer preven-
tion trials. Lancet 361:296-300, 2003
11. Cuzick J, Forbes JF, Sestak I, et al: Long-term
results of tamoxifen prophylaxis for breast cancer:
96-month follow-up of the randomized IBIS-I trial.
J Natl Cancer Inst 99:272-282, 2007
12. Nelson HD, Fu R, Griffin JC, et al: Systematic
review: Comparative effectiveness of medications
to reduce risk for primary breast cancer. Ann Intern
Med 151:703-715, W-226-235, 2009
13. Rutqvist LE, Cedermark B, Glas U, et al:
Contralateral primary tumors in breast cancer
patients in a randomized trial of adjuvant tamox-
ifen therapy. J Natl Cancer Inst 83:1299-1306,
1991
14. Visvanathan K, Chlebowski RT, Hurley P, et al:
American Society of Clinical Oncology clinical prac-
tice guideline update on the use of pharmacologic
interventions including tamoxifen, raloxifene, and
aromatase inhibition for breast cancer risk reduction.
J Clin Oncol 27:3235-3258, 2009
15. King MC, Wieand S, Hale K, et al: Tamoxifen
and breast cancer incidence among women with
inherited mutations in BRCA1 and BRCA2: Na-
tional Surgical Adjuvant Breast and Bowel Project
(NSABP-P1) Breast Cancer Prevention Trial. JAMA
286:2251-2256, 2001
16. Keogh LA, Hopper JL, Rosenthal D, et al: Aus-
tralian clinicians and chemoprevention for women at
Tamoxifen and Risk of Contralateral BC in BRCA1/2 Carriers
www.jco.org © 2013 by American Society of Clinical Oncology 3097
Downloaded from ascopubs.org by 145.5.87.233 on December 18, 2017 from 145.005.087.233
Copyright © 2017 American Society of Clinical Oncology. All rights reserved.
high familial risk for breast cancer. Hered Cancer Clin
Pract 7:9, 2009
17. Goldgar D, Bonnardel C, Renard H, et al: The
International BRCA1/2 Carrier Cohort Study: Pur-
pose, rationale, and study design. http://breast-cancer-
research.com/content/2/6/E010
18. Mann GJ, Thorne H, Balleine RL, et al: Analy-
sis of cancer risk and BRCA1 and BRCA2 mutation
prevalence in the kConFab familial breast cancer
resource. Breast Cancer Res 8:R12, 2006
19. John EM, Hopper JL, Beck JC, et al: The
Breast Cancer Family Registry: An infrastructure
for cooperative multinational, interdisciplinary and
translational studies of the genetic epidemiology
of breast cancer. Breast Cancer Res 6:R375-R389,
2004
20. Dean AG, Sullivan KM, Soe MM: OpenEpi:
Open Source Epidemiologic Statistics for Public
Health, Version 3.01, updated April 6, 2013.
www.OpenEpi.com
21. Chen Y, Thompson W, Semenciw R, et al:
Epidemiology of contralateral breast cancer. Cancer
Epidemiol Biomarkers Prev 8:855-861, 1999
22. Kurian AW, McClure LA, John EM, et al:
Second primary breast cancer occurrence according
to hormone receptor status. J Natl Cancer Inst
101:1058-1065, 2009
23. Malone KE, Begg CB, Haile RW, et al:
Population-based study of the risk of second primary
contralateral breast cancer associated with carrying
a mutation in BRCA1 or BRCA2. J Clin Oncol 28:
2404-2410, 2010
24. Metcalfe K, Gershman S, Lynch HT, et al:
Predictors of contralateral breast cancer in BRCA1
and BRCA2mutation carriers. Br J Cancer 104:1384-
1392, 2011
25. Graeser MK, Engel C, Rhiem K, et al: Con-
tralateral breast cancer risk in BRCA1 and BRCA2
mutation carriers. J Clin Oncol 27:5887-5892, 2009
26. Gronwald J, Tung N, Foulkes WD, et al:
Tamoxifen and contralateral breast cancer in BRCA1
and BRCA2 carriers: An update. Int J Cancer 118:
2281-2284, 2006
27. Reding KW, Bernstein JL, Langholz BM, et al:
Adjuvant systemic therapy for breast cancer in
BRCA1/BRCA2 mutation carriers in a population-
based study of risk of contralateral breast cancer.
Breast Cancer Res Treat 123:491-498, 2010
28. Pierce LJ, Levin AM, Rebbeck TR, et al:
Ten-year multi-institutional results of breast-
conserving surgery and radiotherapy in BRCA1/2-
associated stage I/II breast cancer. J Clin Oncol
24:2437-2443, 2006
29. Metcalfe K, Lynch HT, Ghadirian P, et al:
Contralateral breast cancer in BRCA1 and BRCA2
mutation carriers. J Clin Oncol 22:2328-2335, 2004
30. Mavaddat N, Barrowdale D, Andrulis IL, et al:
Pathology of breast and ovarian cancers among
BRCA1 and BRCA2 mutation carriers: Results from
the Consortium of Investigators of Modifiers of
BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers
Prev 21:134-147, 2012
31. Phillips KA: Immunophenotypic and patho-
logic differences between BRCA1 and BRCA2 he-
reditary breast cancers. J Clin Oncol 18:107S-12S,
2000
32. Asselin-Labat ML, Vaillant F, Sheridan JM, et
al: Control of mammary stem cell function by steroid
hormone signalling. Nature 465:798-802, 2010
33. Li W, Xiao C, Vonderhaar BK, et al: A role of
estrogen/ERalpha signaling in BRCA1-associated
tissue-specific tumor formation. Oncogene 26:7204-
7212, 2007
34. Jones LP, Tilli MT, Assefnia S, et al: Activation
of estrogen signaling pathways collaborates with
loss of Brca1 to promote development of ERalpha-
negative and ERalpha-positive mammary preneopla-
sia and cancer. Oncogene 27:794-802, 2008
35. Antoniou AC, Kartsonaki C, Sinilnikova OM, et
al: Common alleles at 6q25.1 and 1p11.2 are asso-
ciated with breast cancer risk for BRCA1 and BRCA2
mutation carriers. Hum Mol Genet 20:3304-3321,
2011
36. Daidone MG, Veneroni S, Cappelletti V, et al:
Estrogen receptor-beta expression in hereditary
breast cancer. J Clin Oncol 20:3752-3753, 2002;
author reply 3753
37. Litwiniuk MM, Roznowski K, Filas V, et al:
Expression of estrogen receptor beta in the breast
carcinoma of BRCA1 mutation carriers. BMC Cancer
8:100, 2008
38. Murphy LC, Watson PH: Is oestrogen
receptor-beta a predictor of endocrine therapy re-
sponsiveness in human breast cancer? Endocr Relat
Cancer 13:327-334, 2006
39. Noruzinia M, Coupier I, Pujol P: Is BRCA1/
BRCA2-related breast carcinogenesis estrogen de-
pendent? Cancer 104:1567-1574, 2005
40. Meeuwissen PA, Seynaeve C, Brekelmans
CT, et al: Outcome of surveillance and prophylactic
salpingo-oophorectomy in asymptomatic women at
high risk for ovarian cancer. Gynecol Oncol 97:476-
482, 2005
41. Oei AL, Massuger LF, Bulten J, et al: Surveil-
lance of women at high risk for hereditary ovarian
cancer is inefficient. Br J Cancer 94:814-819, 2006
42. Woodward ER, Sleightholme HV, Considine
AM, et al: Annual surveillance by CA125 and trans-
vaginal ultrasound for ovarian cancer in both high-
risk and population risk women is ineffective. BJOG
114:1500-1509, 2007
43. Stirling D, Evans DG, Pichert G, et al: Screen-
ing for familial ovarian cancer: Failure of current
protocols to detect ovarian cancer at an early stage
according to the International Federation of Gyne-
cology and Obstetrics system. J Clin Oncol 23:5588-
5596, 2005
44. van der Velde NM, Mourits MJ, Arts HJ, et al:
Time to stop ovarian cancer screening in BRCA1/2
mutation carriers? Int J Cancer 124:919-923, 2009
45. Cancer Australia: Surveillance of women at
high or potentially high risk of ovarian cancer, 12/
2009. http://canceraustralia.gov.au/about-us/position-
statements/surveillance-women-high-or-potentially-
high-risk
46. Metcalfe KA, Lubinski J, Ghadirian P, et al:
Predictors of contralateral prophylactic mastectomy
in women with a BRCA1 or BRCA2 mutation: The
Hereditary Breast Cancer Clinical Study Group.
J Clin Oncol 26:1093-1097, 2008
47. Kiely BE, Jenkins MA, McKinley JM, et al:
Contralateral risk-reducing mastectomy in BRCA1
and BRCA2 mutation carriers and other high-risk
women in the Kathleen Cuningham Foundation Con-
sortium for Research into Familial Breast Cancer
(kConFab). Breast Cancer Res Treat 120:715-723,
2010
48. Nelson HD, Huffman LH, Fu R, et al: Genetic
risk assessment and BRCA mutation testing for
breast and ovarian cancer susceptibility: System-
atic evidence review for the US Preventive Ser-
vices Task Force. Ann Intern Med 143:362-379,
2005
49. Harvey SL, Francis JE, McBride AJ, et al:
Medication to prevent breast cancer: Too much to
swallow? Med J Aust 195:646-649, 2011
50. Beiner ME, Finch A, Rosen B, et al: The risk of
endometrial cancer in women with BRCA1 and
BRCA2 mutations: A prospective study. Gynecol
Oncol 104:7-10, 2007
51. Duffy DL, Antill YC, Stewart CJ, et al: Report
of endometrial cancer in Australian BRCA1 and
BRCA2 mutation-positive families. Twin Res Hum
Genet 14:111-118, 2011
52. Lu KH, Kauff ND: Does a BRCA mutation plus
tamoxifen equal hysterectomy? Gynecol Oncol 104:
3-4, 2007
Affiliations
Kelly-AnnePhillips, SueAnneMcLachlan,PrueC.Weideman, andKateBirch,PeterMacCallumCancerCentre;Kelly-AnnePhillips,Roger
L.Milne, SueAnneMcLachlan,Melissa C. Southey, and John L.Hopper, University ofMelbourne; SueAnneMcLachlan, St Vincent’sHospital,
Melbourne,Victoria;MichaelL.Friedlander,PrinceofWalesHospital,Randwick,NewSouthWales,Australia;RogerL.Milne, SpanishNational
Cancer Research Centre; Trinidad Caldes, Hospital Clinico San Carlos, Instituto de Investigacio´n Sanitaria San Carlos, Madrid, Spain;Matti A.
Rookus, Netherlands Cancer Institute, Amsterdam; Maartje Hooning and Caroline Seynaeve, Erasmus University Medical Center–Daniel den
Hoed Cancer Center, Rotterdam; Rob A.E.M. Tollenaar, Leiden University Medical Centre, Leiden, the Netherlands; Mary B. Daly, Fox Chase
Cancer Center, Philadelphia, PA; Antonis C. Antoniou, Susan Peock, Debra Frost, Douglas F. Easton, Steve Ellis, University of Cambridge,
Cambridge, United Kingdom; Saundra S. Buys andDavid Goldgar, Huntsman Cancer Institute at the University of Utah, UT; Nadine Andrieu
andDominique Stoppa-Lyonnet, Institut Curie;NadineAndrieu, L’InstitutNational de la Sante´ et de la RechercheMe´dicale, U900;Dominique
Stoppa-Lyonnet, L’Institut National de la Sante´ et de la Recherche Me´dicale, U830; Dominique Stoppa-Lyonnet, Universite´ Paris-Descartes,
Paris;NadineAndrieu,MinesParisTech,Fontainebleau;CatherineNogue`s, InstitutCurie,HoˆpitalRene´Huguenin, StCloud;Vale´rieBonadona,
Universite´ Lyon 1; Vale´rie Bonadona, Centre National de la Recherche Scientifique Unite´ Mixte de Recherche 5558; Vale´rie Bonadona, Centre
Le´on Be´rard, Lyon; Pascal Pujol, Centre Hospitalier Universitaire Arnaud de Villeneuve; Pascal Pujol, L’Institut National de la Sante´ et de la
Recherche Me´dicale 896, Centre de Recherche en Cance´rologie de Marseille Val d’Aurelle, Montpellier, France; Esther M. John, Cancer
Phillips et al
3098 © 2013 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Downloaded from ascopubs.org by 145.5.87.233 on December 18, 2017 from 145.005.087.233
Copyright © 2017 American Society of Clinical Oncology. All rights reserved.
Prevention Institute of California, Fremont; EstherM. John, StanfordUniversity School ofMedicine, Stanford, CA;Mary BethTerry, Columbia
University, New York, NY; Irene L. Andrulis, University of Toronto, Toronto, Ontario; Jacques Simard, Centre Hospitalier Universitaire de
Que´bec and Laval University, Quebec City, Quebec, Canada; Christian F. Singer,Medical University of Vienna, Vienna, Austria; HåkanOlsson,
Lund University, Lund, Sweden; Anna Jakubowska, Pomeranian Medical University, Szczecin, Poland; Edith Olah, National Institute of
Oncology, Budapest, Hungary; Anne-Marie Gerdes, Rigshospitalet and Copenhagen University, Copenhagen, Denmark; and Lenka Foretova,
MasarykMemorial Cancer Institute, Brno, Czech Republic.
Support
Supported by the (Australian) National Breast Cancer Foundation and Cancer Australia Grant No. 628333. International BRCA1 and
BRCA2 Carrier Cohort Study (IBCCS) –Epidemiological Study of BRCA1 and BRCA2 Mutation Carriers, UK (EMBRACE) is supported by
Cancer Research UK Grants No. C1287/A10118 and C1287/A11990. IBCCS–Gene Etude Prospective Sein Ovaire, France (GENEPSO) is
supportedby theFondationdeFrance and theLigueNationaleContre leCancer. IBCCS–HereditaryBreast andOvarianCancerResearchGroup
Netherlands (HEBON) is supported by Dutch Cancer Society Grants No. NKI1998 1854, NKI2004-3088, NKI2007-3756 and the Netherlands
Organization for Scientific Research Grant No. NWO/91109024. IBCCS–Interdisciplinary Health Research Internal Team Breast Cancer
Susceptibility Study (INHERIT)was supportedby theCanadian Institutes ofHealthResearch for the INHERITBRCAs researchprogram(Grant
No.CRT43822) andCanadian InstituteHealthResearch (CIHR)Team inFamilial Risks of BreastCancer program(GrantNo.CRN87521), the
Canadian Breast Cancer Research Alliance (Grant No. 019511), and the Ministry of Economic Development, Innovation and Export Trade
(Grant No. PSR-SIIRI 701). IBCCS–National Institute of Oncology (NIO) Hungary was funded by European Against Cancer (subcontract
between International Agency for Research on Cancer Lyon andNIO Budapest). This study at NIO, Budapest, Hungary, was supported in part
byNorwegianEuropeanEconomicArea (EEA)FinancialMechanism(GrantNo.HU0115/NA/2008-3/ÖP-9). IBCCS-Brno,MasarykMemorial
Cancer Institute (MMCI), Czech Republic was supported by IBCCS and by the European Regional Development Fund and the State Budget of
the Czech Republic (Regional Center for Applied Molecular Oncology [RECAMO], Grant No. CZ.1.05/2.1.00/03.0101). IBCCS–Molecular
Oncology Laboratory, Madrid (MOL) was supported by Grant No. RD06/0020/0021 fromRed Tematica Investigacion Cooperative en Cancer
(RTICC; ISCIII), Spanish Ministry of Economy and Competitivity. The Kathleen Cuningham Foundation Consortium for Research into
Familial Breast Cancer (kConFab) and the kConFab Follow-UpStudy are supported by grants from theNational Breast Cancer Foundation, the
National Health and Medical Research Council, and by the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria,
Tasmania, and South Australia, and the Cancer Foundation ofWestern Australia. The Breast Cancer Family Registry (BCFR) was supported by
theNationalCancer Institute,National InstitutesofHealthunderGrantNo.UMICA164920andthroughcooperativeagreementswithmembers
of the BCFR and principal investigators, including Cancer Care Ontario (Grant No. U01 CA69467), Cancer Prevention Institute of California
(Grant No. U01 CA69417), Columbia University (Grant No. U01 CA69398), Fox Chase Cancer Center (Grant No. U01 CA69631), Huntsman
Cancer Institute (Grant No. U01 CA69446), the University of Melbourne (Grant No. U01 CA69638), and Georgetown University Medical
Center Informatics Support Center (Grant No. HHSN261200900010C).
■ ■ ■
Tamoxifen and Risk of Contralateral BC in BRCA1/2 Carriers
www.jco.org © 2013 by American Society of Clinical Oncology 3099
Downloaded from ascopubs.org by 145.5.87.233 on December 18, 2017 from 145.005.087.233
Copyright © 2017 American Society of Clinical Oncology. All rights reserved.
Acknowledgment
We thank all the participants in these studies and all the researchers, clinicians, technicians, and administrative staff who have enabled this
work tobe carriedout. Inparticular, the InternationalBRCA1 andBRCA2CarrierCohort Study (IBCCS) acknowledgesMarie-JoséBlomforher
solid work as the central data manager of this collaborative study; IBCCS–Interdisciplinary Health Research Internal Team Breast Cancer
Susceptibility Study (INHERIT)acknowledgesMartineDumont formanagingepidemiologic andpathologicdata collectedbyCancerGenomics
Laboratory research nurses, Quebec City, Canada; IBCCS-Brno, MasarykMemorial Cancer Institute (MMCI), Czech Republic, acknowledges
Dita Hanouskova, Jitka Berkovcova, and other staff members for their consulting work with families, data collection, and data entry; IBCCS
Poland acknowledges allmembers and collaborators of the InternationalHereditaryCancerCentre, Szczecin, Poland; IBCCS–National Institute
of Oncology (NIO), Hungary, acknowledgesMiklos Kasler for his support of the study andMarie Balogh Kovacs for her help in submission of
IBCCS questionnaires; T.C. acknowledges Pedro Perez Seguar,MD, for his clinical work; theKathleenCuninghamFoundationConsortium for
Research into Familial Breast Cancer (kConFab) acknowledges Lucy Stanhope, Heather Thorne, Eveline Niedermayr, the kConFab research
nurses and staff, the heads and staff of the Family Cancer Clinics, and the families for their contributions to the resource.
Appendix
K.-A.P. is a National Breast Cancer Foundation Practitioner Fellow; A.C.A. is a Cancer Research–United Kingdom Senior Cancer
Research Fellow (C12292/A11174); D.F.E. is a Cancer Research–United KingdomPrincipal Research Fellow; I.L.A. is the Anne andMax
Tanenbaum Chair in Molecular Medicine at Mount Sinai Hospital; J.S. is Chairholder of the Canada Research Chair in Oncogenetics;
J.L.H. is anAustralia Fellow;M.C.S. is a SeniorResearchFellowof theNationalHealth andMedical ResearchCouncil ofAustralia;M.C.S.
and J.L.H. are Group Leaders of the Victorian Breast Cancer Research Consortium.
Epidemiological Study of BRCA1 and BRCA2Mutation Carriers, UK (EMBRACE) Collaborating Centers are as follows:Coordinating
Centre, Cambridge: Susan Peock, Debra Frost, Steve Ellis, Elena Fineberg, Radka Platte. North of Scotland Regional Genetics Service,
Aberdeen:ZosiaMiedzybrodzka,HelenGregory.Northern IrelandRegionalGenetics Service,Belfast: PatrickMorrison,Lisa Jeffers.West
MidlandsRegionalClinicalGenetics Service, Birmingham:TrevorCole, Kai-renOng, JonathanHoffman. SouthWest RegionalGenetics
Service, Bristol: AlanDonaldson,Margaret James. East AnglianRegionalGenetics Service, Cambridge:MarcTischkowitz, JoanPaterson,
Amy Taylor. Medical Genetics Services for Wales, Cardiff: Alexandra Murray, Mark T. Rogers, Emma McCann. St James’s Hospital,
Dublin & National Centre for Medical Genetics, Dublin: M. John Kennedy, David Barton. South East of Scotland Regional Genetics
Service, Edinburgh:Mary Porteous, SarahDrummond. Peninsula Clinical Genetics Service, Exeter: Carole Brewer, EmmaKivuva, Anne
Searle, Selina Goodman, Kathryn Hill. West of Scotland Regional Genetics Service, Glasgow: Rosemarie Davidson, Victoria Murday,
Nicola Bradshaw, Lesley Snadden,Mark Longmuir, CatherineWatt, SarahGibson, EshikaHaque, EdTobias, Alexis Duncan. South East
Thames Regional Genetics Service, Guy’sHospital London: Louise Izatt, Chris Jacobs, Caroline Langman.NorthWest Thames Regional
Genetics Service, Harrow: Angela Brady, Huw Dorkins, Athalie Melville, Kashmir Randhawa. Leicestershire Clinical Genetics Service,
Leicester: Julian Barwell. Yorkshire Regional Genetics Service, Leeds: Julian Adlard, Gemma Serra-Feliu. Cheshire &Merseyside Clinical
Genetics Service, Liverpool: Ian Ellis, Catherine Houghton. Manchester Regional Genetics Service, Manchester: D. Gareth Evans, Fiona
Lalloo, Jane Taylor. North East Thames Regional Genetics Service, NE Thames, London: Lucy Side, Alison Male, Cheryl Berlin.
NottinghamCentre forMedicalGenetics,Nottingham: JacquelineEason,RebeccaCollier.NorthernClinicalGenetics Service,Newcastle:
FionaDouglas,OonaghClaber, Irene Jobson.OxfordRegionalGenetics Service,Oxford: LisaWalker,DianeMcLeod,DorothyHalliday,
Sarah Durell, Barbara Stayner. The Institute of Cancer Research and Royal Marsden NHS Foundation Trust: Rosalind A. Eeles, Susan
Shanley, NazneenRahman, RichardHoulston, Elizabeth Bancroft, Elizabeth Page, Audrey Ardern-Jones, Kelly Kohut, JenniferWiggins,
Elena Castro, Emma Killick, Sue Martin, Gillian Rea, Anjana Kulkarni. North Trent Clinical Genetics Service, Sheffield: Jackie Cook,
Oliver Quarrell, Cathryn Bardsley. South West Thames Regional Genetics Service, London: Shirley Hodgson, Sheila Goff, Glen Brice,
LizzieWinchester, Charlotte Eddy, Vishakha Tripathi, Virginia Attard, Anna Lehmann.Wessex Clinical Genetics Service, Princess Anne
Hospital, Southampton: Diana Eccles, Anneke Lucassen, Gillian Crawford, DonnaMcBride, Sarah Smalley. D. Gareth Evans and Fiona
Lalloo are supported by an NIHR grant to the Biomedical Research Centre, Manchester. The Investigators at The Institute of Cancer
Research and The Royal Marsden NHS Foundation Trust are supported by an NIHR grant to the Biomedical Research Centre at The
Institute of Cancer Research and The RoyalMarsdenNHS Foundation Trust. Rosalind A. Eeles and Elizabeth Bancroft are supported by
Cancer Research United Kingdom (Grant C5047/A8385).
The Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON) consists of the following Collaborating Centers:
Coordinatingcenter:NetherlandsCancer Institute,Amsterdam,NL:M.A.Rookus,F.B.L.Hogervorst, F.E. vanLeeuwen,S.Verhoef,M.K.
Schmidt, J.L. de Lange; Erasmus Medical Center, Rotterdam, NL: J.M. Colle´e, A.M.W. van den Ouweland, M.J. Hooning, C. Seynaeve,
C.H.M.vanDeurzen;LeidenUniversityMedicalCenter,NL:C.J. vanAsperen, J.T.Wijnen,R.A.E.M.Tollenaar,P.Devilee,T.C.T.E.F. van
Cronenburg; RadboudUniversityNijmegenMedical Center,NL:C.M.Kets, A.R.Mensenkamp;UniversityMedical CenterUtrecht,NL:
M.G.E.M. Ausems, R.B. van der Luijt; Amsterdam Medical Center, NL: C.M. Aalfs, T.A.M. van Os; VU University Medical Center,
Amsterdam, NL: J.J.P. Gille, Q. Waisfisz, H.E.J. Meijers-Heijboer; University Hospital Maastricht, NL: E.B. Go´mez-Garcia, M.J. Blok;
UniversityMedicalCenterGroningen,NL: J.C.Oosterwijk,A.H. vanderHout,M.J.Mourits,G.H.deBock.TheNetherlandsFoundation
for the detection of hereditary tumors, Leiden, NL: H.F. Vasen.
Phillips et al
© 2013 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Downloaded from ascopubs.org by 145.5.87.233 on December 18, 2017 from 145.005.087.233
Copyright © 2017 American Society of Clinical Oncology. All rights reserved.
Gene Etude Prospective Sein Ovaire, France (GENEPSO) Collaborating Centers are as follows: Coordinating Center, Hoˆpital Rene´
Huguenin/Institut Curie,Saint Cloud: Catherine Nogue`s, Emmanuelle Fourme, Rosette Lidereau; Etienne Rouleau, Sandrine Caputo,
ShirleyWakselman, Collaborating Centers: Institut Curie, Paris: Dominique Stoppa-Lyonnet,MarionGauthier-Villars; Bruno Buecher,
Institut Gustave Roussy, Villejuif :Olivier Caron; Hoˆpital Rene´ Huguenin/Institut Curie, Saint Cloud: Catherine Nogue`s, Liliane
Demange; Centre Paul Strauss, Strasbourg: Jean-Pierre Fricker; Centre Le´on Be´rard, Lyon: Christine Lasset, Vale´rie Bonadona; Centre
Franc¸ois Baclesse, Caen: Pascaline Berthet; Hoˆpital d’Enfants CHU Dijon – Centre Georges Franc¸ois Leclerc, Dijon: Laurence Faivre;
Centre Alexis Vautrin, Vandoeuvre-les-Nancy: Elisabeth Luporsi; Centre Antoine Lacassagne, Nice: Marc Fre´nay; Institut Claudius
Regaud, Toulouse: Laurence Gladieff; Re´seau Oncoge´ne´tique Poitou Charente, Niort: Paul Gesta; Institut Paoli-Calmettes, Marseille:
Hagay Sobol, Franc¸ois Eisinger, Laetitia Huiart; Institut Bergonie´, Bordeaux:Michel Longy, Centre Euge`neMarquis, Rennes: Catherine
Dugast; GHPitie´ Salpe´trie`re, Paris: Chrystelle Colas, Florent Soubrier; CHUArnaud deVilleneuve,Montpellier: Isabelle Coupier, Pascal
Pujol; Centres Paul Papin, and Catherine de Sienne, Angers, Nantes: Alain Lortholary; Centre Oscar Lambret, Lille: Philippe Vennin,
Claude Adenis; Institut Jean Godinot, Reims: Tan Dat Nguyen; Centre Rene´ Gauducheau, Nantes: Capucine Delnatte; Centre Henri
Becquerel, Rouen: Annick Rossi, Julie Tinat, Isabelle Tennevet; Hoˆpital Civil, Strasbourg: Jean-Marc Limacher; Christine Maugard;
Hoˆpital Centre Jean Perrin, Clermont-Ferrand: Yves-Jean Bignon; Polyclinique Courlancy, Reims: Liliane Demange; Clinique Sainte
Catherine,Avignon:He´le`neDreyfus;Hoˆpital Saint-Louis, Paris:OdileCohen-Haguenauer;CHRUDupuytren,Limoges:BrigitteGilbert;
Couple-Enfant-CHU de Grenoble: Dominique Leroux; Hoˆpital de la Timone, Marseille: He´le`ne Zattara-Cannoni; Inserm U900, Ecole
desMines deParis, ParisTech, Service deBiostatistiques, InstitutCurie, Paris:NadineAndrieu; InsermU535,Villejuif: CatherineBonaïti;
InsermU379, Marseille: Claire Julian-Reynier; Inserm.
Tamoxifen and Risk of Contralateral BC in BRCA1/2 Carriers
www.jco.org © 2013 by American Society of Clinical Oncology
Downloaded from ascopubs.org by 145.5.87.233 on December 18, 2017 from 145.005.087.233
Copyright © 2017 American Society of Clinical Oncology. All rights reserved.
